Fedorenko E The early origins and the growing popularity of the individual-subject analytic approach in human neuroscience. Current Opinion in Behavioral Sciences. 2021; 40:105-112.
Gratton C, Nelson SM, Gordon EM Brain-behavior correlations: Two paths toward reliability. Neuron. 2022 May 4;110(9):1446-1449. doi: 10.1016/j.neuron.2022.04.018.
Itthipuripat S, Vo VA, Sprague TC, Serences JT Value-driven attentional capture enhances distractor representations in early visual cortex. PLoS Biol. 2019 Aug 9;17(8):e3000186. doi: 10.1371/journal.pbio.3000186. eCollection 2019 Aug.
Mackey WE, Winawer J, Curtis CE Visual field map clusters in human frontoparietal cortex. Elife. 2017 Jun 19;6:e22974. doi: 10.7554/eLife.22974.
Naselaris T, Allen E, Kay K Extensive sampling for complete models of individual brains. Current Opinion in Behavioral Sciences. 2021; 40:45-51.
Poldrack RA Diving into the deep end: a personal reflection on the MyConnectome study. Current Opinion in Behavioral Sciences. 2021; 40:1-4.
Poltoratski S, Ling S, McCormack D, Tong F Characterizing the effects of feature salience and top-down attention in the early visual system. J Neurophysiol. 2017 Jul 1;118(1):564-573. doi: 10.1152/jn.00924.2016. Epub 2017 Apr 5.
Poltoratski S, Tong F Resolving the Spatial Profile of Figure Enhancement in Human V1 through Population Receptive Field Modeling. J Neurosci. 2020 Apr 15;40(16):3292-3303. doi: 10.1523/JNEUROSCI.2377-19.2020. Epub 2020 Mar 5.
Pritschet L, Taylor CM, Santander T, Jacobs EG Applying dense-sampling methods to reveal dynamic endocrine modulation of the nervous system. Curr Opin Behav Sci. 2021 Aug;40:72-78. doi: 10.1016/j.cobeha.2021.01.012. Epub 2021 Feb 25.
Smith PL, Little DR Small is beautiful: In defense of the small-N design. Psychon Bull Rev. 2018 Dec;25(6):2083-2101. doi: 10.3758/s13423-018-1451-8.
Sprague TC, Adam KCS, Foster JJ, Rahmati M, Sutterer DW, Vo VA Inverted Encoding Models Assay Population-Level Stimulus Representations, Not Single-Unit Neural Tuning. eNeuro. 2018 Jun 5;5(3):ENEURO.0098-18.2018. doi: 10.1523/ENEURO.0098-18.2018. eCollection 2018 May-Jun. No abstract available.
Sprague TC, Boynton GM, Serences JT The Importance of Considering Model Choices When Interpreting Results in Computational Neuroimaging. eNeuro. 2019 Dec 20;6(6):ENEURO.0196-19.2019. doi: 10.1523/ENEURO.0196-19.2019. Print 2019 Nov/Dec.
Sprague TC, Itthipuripat S, Vo VA, Serences JT Dissociable signatures of visual salience and behavioral relevance across attentional priority maps in human cortex. J Neurophysiol. 2018 Jun 1;119(6):2153-2165. doi: 10.1152/jn.00059.2018. Epub 2018 Feb 28.
Sprague TC, Serences JT Attention modulates spatial priority maps in the human occipital, parietal and frontal cortices. Nat Neurosci. 2013 Dec;16(12):1879-87. doi: 10.1038/nn.3574. Epub 2013 Nov 10.
Probing the Role of Feature Dimension Maps in Visual Cognition: Expt 1.1
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.